VECTION TECHNOLOGIES LTD — Regulatory Filings 2021

Mar 18, 2021

19 March 2021 | Australia

==> picture [130 x 44] intentionally omitted <==

ASX RELEASE

ADDITIONAL INFORMATION ON THE HEALTHCARE & PHARMA DIVISION

On 11 March 2021, real-time software company Vection Technologies Ltd ( ASX:VR1 ) ( Vection Technologies , Vection or the Company ) announced the acceleration of its Verticalization growth strategy with the launch of its Healthcare & Pharma Solutions division.

Further the announcement dated 11 March 2021, the Company provides the following additional information:

• Following extensive negotiations, the Company has secured the strong commitment of Dr Centemeri through the incorporation of a joint venture company controlled by Vection at 60%, with 40% owned by Dr Centemeri ( Division ), a leading healthcare and pharma executive with senior experience in BASF, Knoll Pharmaceuticals, Abbott Laboratories, Bristol-Myers Squibb and AstraZeneca.

• The key terms of the agreement with Dr Centemeri consist of his involvement in the new Division and his commitment as its Managing Director, to the achievement of expansion of Vection’s footprint in the healthcare, pharmaceutical, biotechnological, medical devices and nutraceutical market segments as disclosed, which forms the basis of a comprehensive results driven business plan which is an integral part of his commitment.

• Vection will provide funding for establishment costs of the Division pursuant to a comprehensive business plan underpinned by the commitment of Dr Centemeri. The initial agreement provides for the commitment of Dr Centemeri, the composition of the new Division, exclusivity, non-competition, business plan and cash flows and activities of the new company.

==> picture [25 x 25] intentionally omitted <==

3D VIRTUAL REALITY AUGMENTED REALITY INDUSTRIAL IoT CAD

• Vection controls the new Division on the basis of holding a 60% shareholding and retaining control of its board. The board composition is Dr Centemeri and 2 appointees of Vection.

Vection Technologies Investor Relations Contact Details

Gianmarco Biagi - Managing Director (Europe Based) Email: gianmarco.biagi@vection.com.au Phone: +39 051 0142248

Gianmarco Orgnoni - Director and COO (Australia Based) Email: gianmarco.orgnoni@vection.com.au Phone: +61 8 6380 2555

ENDS

Vection Technologies Ltd (ASX:VR1) ACN: 614 814 041

Media Enquiries AUpress@vection.com.au EUpress@vection.com.au

==> picture [23 x 35] intentionally omitted <==

1

Address: 642 Newcastle Street, Leederville WA 6007

Europe North America Address: Via Isonzo 61 Address: 785 Market Street, #600 40033 Casalecchio di Reno (BO), San Francisco CA 94103 Italy USA

Phone: +618 6380 2555

==> picture [130 x 44] intentionally omitted <==

About Vection Technologies:

Vection Technologies Ltd (ASX:VR1) is a multinational software company that focuses on real-time technologies for industrial companies’ digital transformation.

Through a combination of our 3D, Virtual Reality, Augmented Reality, Industrial IoT and CAD solutions, Vection Technologies helps companies and organisations to innovate, collaborate and create value.

For more information please visit the Company’s websites:

vection.com.au

mindeskvr.com

ASX release authorised by the Board of Directors of Vection Technologies Ltd.

==> picture [25 x 25] intentionally omitted <==

3D VIRTUAL REALITY AUGMENTED REALITY INDUSTRIAL IoT CAD

Vection Technologies Ltd (ASX:VR1) ACN: 614 814 041

Media Enquiries AUpress@vection.com.au EUpress@vection.com.au

==> picture [23 x 35] intentionally omitted <==

2

North America Address: 785 Market Street, #600 San Francisco CA 94103 USA

Europe Address: Via Isonzo 61 40033 Casalecchio di Reno (BO), Italy

Address: 642 Newcastle Street, Leederville WA 6007 Phone: +618 6380 2555